Understanding migraine, optimising outcomes

Despite increased understanding of migraine pathophysiology and the link between neuropeptides and the disease progression to chronic migraine, as well as the rise of migraine-specific treatment options that target neuropeptides such as calcitonin gene-related peptide (CGRP), choosing the right treatment for each patient can remain a challenge.

In this engaging Lundbeck-sponsored satellite symposium, Patricia Pozo-Rosich (Chair), Peter Goadsby and Jessica Ailani will explore the link between neuropeptides and migraine disease progression.  They will discuss the rise of anti-CGRP therapies and their impact on patients, as well as reviewing data on current treatment options and how we might match the right treatment to the right patient.  They will also discuss the importance of long-term patient-centric management, ongoing evaluation of treatment outcomes and what the future might hold for migraine-specific treatments.  The session will end with an audience Q&A.